1. Home
  2. AOD vs ABUS Comparison

AOD vs ABUS Comparison

Compare AOD & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn Total Dynamic Dividend Fund of Beneficial Interest

AOD

abrdn Total Dynamic Dividend Fund of Beneficial Interest

HOLD

Current Price

$10.62

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.13

Market Cap

888.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AOD
ABUS
Founded
N/A
2005
Country
US
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
888.5M
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
AOD
ABUS
Price
$10.62
$4.13
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
N/A
1.8M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$125.30
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
N/A
$2.71
52 Week High
N/A
$5.10

Technical Indicators

Market Signals
Indicator
AOD
ABUS
Relative Strength Index (RSI) 77.26 48.29
Support Level $10.26 $3.93
Resistance Level $10.39 $4.34
Average True Range (ATR) 0.12 0.33
MACD 0.05 0.03
Stochastic Oscillator 99.35 57.73

Price Performance

Historical Comparison
AOD
ABUS

About AOD abrdn Total Dynamic Dividend Fund of Beneficial Interest

Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. The fund invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, and Industrials among other sectors.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: